Sabra Healthcare REIT (SBRA) Stock Price, News & Analysis

Company Overview

Sabra Healthcare REIT, Inc. is a self-managed real estate investment trust that owns and invests in healthcare-related real estate. The company primarily provides capital to healthcare operators through property ownership, leases, mortgage loans, and other investment structures.

Sabra’s portfolio has historically included skilled nursing facilities, senior housing communities, behavioral health facilities, specialty hospitals, and other healthcare properties. Its properties are generally leased to or operated by third-party healthcare providers, allowing the company to participate in the healthcare real estate market without directly delivering most patient-care services.

Founded in 2010, Sabra Healthcare REIT serves healthcare markets primarily in the United States, with investments that have also included select properties in Canada. The company is headquartered in Irvine, California, and is led by Richard K. Matros, who serves as chief executive officer and chairman.

Key Stats

• Today's Range: $19.01 to $19.42
• 50-Day Range: $19.16 to $22.39
• 52-Week Range: $17.17 to $22.77
• Volume: 3.01 million shs
• Average Volume: 2.42 million shs
• Market Capitalization: $4.89 billion
• P/E Ratio: 73.70
• Dividend Yield: 6.26%
• Price Target: $22.23
• Consensus Rating: Moderate Buy

Sabra Healthcare REIT Stock Analysis - MarketRank™

Sabra Healthcare REIT scored higher than 52% of companies evaluated by MarketBeat, and ranked 131st out of 186 stocks in the real estate sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Sabra Healthcare REIT has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 7 buy ratings, 7 hold ratings, and no sell ratings.

Upside Potential

Sabra Healthcare REIT has a consensus price target of $22.23, representing about 16.0% upside from its current price of $19.16.

Amount of Analyst Coverage

Sabra Healthcare REIT has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: 5.26%

Earnings Growth

Earnings for Sabra Healthcare REIT are expected to grow by 5.26% in the coming year, from $1.52 to $1.60 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sabra Healthcare REIT is 73.70, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.65.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sabra Healthcare REIT is 73.70, which means that it is trading at a more expensive P/E ratio than the Real Estate sector average P/E ratio of about 27.00.

Price to Earnings Growth Ratio

Sabra Healthcare REIT has a PEG Ratio of 1.45. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Sabra Healthcare REIT has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.32% of the float of Sabra Healthcare REIT has been sold short.

Short Interest Ratio / Days to Cover

Sabra Healthcare REIT has a short interest ratio ("days to cover") of 9.12.

Change versus previous month

Short interest in Sabra Healthcare REIT has recently increased by 8.45%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Leadership

Sabra Healthcare REIT is a leading dividend payer. It pays a dividend yield of 6.26%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Sabra Healthcare REIT does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Sabra Healthcare REIT is 461.54%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, Sabra Healthcare REIT will have a dividend payout ratio of 75.00% next year. This indicates that Sabra Healthcare REIT will be able to sustain or increase its dividend.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

Search Interest

4 people have searched for SBRA on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

5 people have added Sabra Healthcare REIT to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Sabra Healthcare REIT insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,166,000.00 in company stock.

Percentage Held by Insiders

1.09% of the stock of Sabra Healthcare REIT is held by insiders.

Percentage Held by Institutions

99.40% of the stock of Sabra Healthcare REIT is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/03/2026
• Record date for 8/31 Dividend: 8/14/2026
• Ex-Dividend for 8/31 Dividend: 8/14/2026
• Dividend Payable: 8/31/2026
• Today: 10/04/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Real Estate
• Industry: Healthcare REITs
• Sub-Industry: Healthcare REITs
• Current Symbol: NASDAQ:SBRA
• CIK: 1492298
• Web: www.sabrahealth.com
• Phone: (888) 393-8248
• Fax: 949-679-8868
• Employees: 58
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Sabra Healthcare REIT: $22.23
• High Price Target: $25.00
• Low Price Target: $19.00
• Potential Upside/Downside: +16.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.26
• Trailing P/E Ratio: 73.70
• Forward P/E Ratio: 12.61
• P/E Growth: 1.45
• Net Income: $155.61 million
• Net Margins: 7.61%
• Pretax Margin: 7.02%
• Return on Equity: 2.34%
• Return on Assets: 1.18%

Debt

• Debt-to-Equity Ratio: 0.95
• Current Ratio: 3.07
• Quick Ratio: 3.07

Sales & Book Value

• Annual Sales: $774.63 million
• Price / Sales: 6.32
• Cash Flow: $1.37 per share
• Price / Cash Flow: 13.94
• Book Value: $11.32 per share
• Price / Book: 1.69

Miscellaneous

• Outstanding Shares: 255,460,000
• Free Float: 252,678,000
• Market Cap: $4.89 billion
• Optionable: Optionable
• Beta: 0.63